Market Movement Analysis: COMPASSPathways surges on September 17 as COMP360 Phase III and commercialization approach

1. On September 14, the company released the Part C data of COMP005 Phase III trial. One year after a single 25 mg dose of COMP360, the average MADRS score decreased by 13 points, with 40%-45% achieving at least a 50% response, and about 30% achieving remission. Safety was consistent with previous stages.
2. On September 15, the company stated that COMP360 shows rapid and durable efficacy for treatment-resistant depression, with a low number of annual doses required. The company plans to complete FDA submission in Q4 2026 and expects market launch in the first half of 2027. The company mainly develops new therapies for mental health and its PTSD project is progressing steadily.
3. On September 16, company management attended the Morgan Stanley Global Healthcare Conference, continuously presenting updates on the COMP360 clinical program and progress in mental health treatment.

(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)